A1 Refereed original research article in a scientific journal
HSF2 drives breast cancer progression by acting as a stage-specific switch between proliferation and invasion
Authors: Pessa, Jenny C.; Paavolainen, Oona; Hästbacka, Hendrik S. E.; Puustinen, Mikael C.; Da Silva, Alejandro J.; Pihlström, Sandra; Gramolelli, Silvia; Boström, Pia; Hartiala, Pauliina; Peuhu, Emilia; Joutsen, Jenny; Sistonen, Lea
Publisher: American Association for the Advancement of Science (AAAS)
Publication year: 2025
Journal: Science Advances
Article number: eady1289
Volume: 11
Issue: 36
eISSN: 2375-2548
DOI: https://doi.org/10.1126/sciadv.ady1289
Publication's open availability at the time of reporting: Open Access
Publication channel's open availability : Open Access publication channel
Web address : https://doi.org/10.1126/sciadv.ady1289
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/500091980
Breast cancer is hallmarked by phenotypic transitions enabling abnormal cell proliferation and invasion. The stress-protective transcription factor heat shock factor 2 (HSF2) is associated with cancer, but its function in breast carcinogenesis remains poorly understood. Analysis of human breast tumor samples and mouse in vivo xenografts uncovered that HSF2 expression and activity undergo dynamic changes as a function of tumor progression. HSF2 expression, nuclear localization, and coexpression with the proliferation marker Ki67 are increased in ductal carcinoma in situ (DCIS), suggesting that HSF2 designates hyperplastic cells underlying tumor expansion. In mouse xenografts, HSF2 localization switches from nuclear to cytoplasmic upon DCIS-to-invasive transition. Using cell-based models, we identify canonical transforming growth factor–β (TGF-β) signaling as the molecular mechanism regulating HSF2. TGF-β–mediated down-regulation of HSF2 allowed acquisition of an invasive cell phenotype, which was counteracted by ectopic HSF2. Together, we propose that HSF2 acts as a stage-specific switch between proliferation and invasion in breast cancer.
Downloadable publication This is an electronic reprint of the original article. |  |
Funding information in the publication:
This work was supported by the Research Council of Finland (S.G., E.P., and L.S.); Sigrid Jusélius Foundation (E.P. and L.S.); Cancer Foundation Finland (E.P. and L.S.); Jane and Aatos Erkko Foundation (E.P. and L.S.); Åbo Akademi University funded Doctoral Position (J.C.P.); The Finnish Cultural Foundation, Kymenlaakso Regional Fund (J.C.P.); Turku Doctoral Program in Molecular Medicine (O.P.); Swedish Cultural Foundation (M.C.P.); K. Albin Johansson’s Foundation (H.S.E.H., M.C.P., and A.J.D.S.); Magnus Ehrnrooth Foundation (A.J.D.S.); The Medical Research Foundation Liv och Hälsa (A.J.D.S. and L.S.); Finnish Cultural Foundation (A.J.D.S. and S.G.); The Finnish Cultural Foundation, Lapland Regional Fund (J.J.); Lapland Hospital District Research Grant (J.J.); and The Hospital District of Southwestern Finland (E.P.).
